- ElectroCore Inc (NASDAQ: ECOR) and the Hospital Clínico Universitario de Valencia in Spain have completed the enrollment in the SAVIOR-1 study. This study was supported in part by electroCore.
- The randomized, controlled study evaluates the effect of non-invasive electrical vagus nerve stimulation (nVNS) on respiratory symptoms due to COVID-19.
- In July last year, gammaCore SapphireTM CV (the nVNS) received emergency use authorization from the FDA to treat patients with known or suspected COVID-19 who are experiencing an exacerbation of asthma-related dyspnea and reduced airflow.
- Price Action: ECOR increased 10.2% at $2.325 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
